Objective To seek differentially expressed proteins for human epithelial growth factorreceptor-2 (HER-2)negative and positive breast carcinoma through establishing proteins profiles,and to providenew prognostic markers and therapeutic targets for patients with breast cancer.Methods HER-2 positiveand negative breast cancer protein expression profiles were established using proteomic isobaric tags for relativeand absolute quantitation (iTRAQ)technology.Differences of protein expression were identified and parts ofdifferential expression proteins were analyzed by bio-informatics,including protein function annotation and GOclassification analysis and Kyoto Encyclopedia of Gene and Genome (KEGG)pathway analysis.Results Proteomicanalysis of breast cancer tissue with identified HER-2 positive and negative groups showed 4 999 differentiallyexpressed proteins by iTRAQ.Based on the criteria of the ratio of HER-2(+)/HER-2(-)≥3,119up-regulated proteins were identified in HER-2 positive group.Based on the criteria of the ratio of HER-2(+)/HER-2(-)≤0.5,47 down-regulated proteins were identified in HER-2 positive group.The results ofGO analysis showed that the molecular function,biological process and cellular composition of differentiallyexpressed proteins were complex between HER-2 positive and negative breast cancer.There were differences inthe distribution of up-regulated proteins and down-regulation of proteins.KEGG pathway analysis showed thatdifferentially expressed proteins involved in 168 signal pathways.Conclusion There are differentiallyexpressed proteins between HER-2 positive and negative breast cancer,which involve complex molecular func-tion,biological process and signaling pathway.

Objective To investigate the expression and clinical significance of microRNA-210 (miR-210)in breast cancer tissues,and to investigate its effect on the proliferation and metastasis of human triple negative breast cancer cell line MDA-MB-231 in vitro. Methods The breast cancer tissues and paracancerous tissues in 82 patients were collected in the Department of Pathology of Hunan Cancer Hospital from December 2013 to September 2015. Quantitative real-time polymerase chain reaction (qRT-PCR)technique was used to detect the expression level of miR-210 in tissues and cells. The relationship between the expression of miR-210 and clinical data and prognosis of patients were analyzed. The triple negative breast cancer cell line MDA-MB-231 transfected with full-length miR-210 plasmid was regarded as test group,and the cell transfected with blank vector was regarded as control group. CCK-8 assay was used to detect the proliferation ability of cells in both groups. Transwell invasion and migration assays were used to detect the metastasis and invasion ability of cells. Results The results of qRT-PCR showed that the expression level of miR-210 was 0. 198 ± 0. 014 in breast cancer tissues,which was significantly higher than that in paracancerous tissues (0. 084 ± 0. 009),and the difference was statistically significant (t = 8. 141,P < 0. 001). The expression level of miR-210 in triple nega-tive breast cancer tissues was 0. 254 ± 0. 026,which was significantly higher than that in non-triple negative breast cancer tissues (0. 167 ± 0. 015),and the difference was statistically significant (t = 3. 175,P =0. 003). There were significant differences in TNM staging and molecular typing between the patients with high and low expression of miR-210 (χ2 = 7. 859,P = 0. 005;χ2 = 7. 053,P = 0. 008). The 4-year survival rate of patients with high expression of miR-210 was significantly lower than that of patients with low expression of miR-210 (49. 37％ vs. 76. 80％),and the difference was statistically significant (χ2 = 4. 743,P = 0. 024). The results of qRT-PCR showed that the expression of miR-210 in cells in test group was 0. 517 ± 0. 038,which was significantly higher than that in control group (0. 284 ± 0. 022),and the difference was statistically significant (t = 9. 280,P < 0. 001). The results of CCK-8 assay showed that the proliferation abilities of the test group were significantly higher than those of the control group in 48,72 and 96 h (3. 771 ± 0. 452 vs. 3. 206 ± 0. 314;7. 662 ± 0. 619 vs. 6. 736 ± 0. 552;15. 477 ± 1. 425 vs. 11. 592 ± 1. 243),and the differences were statistically significant (t = 2. 296,P = 0. 025;t = 2. 496,P = 0. 019;t = 4. 594,P = 0. 001). The results of Transwell invasion assay showed that the cell number of test group in inferior surface was 107. 8 ± 13. 0,which was significantly higher than that of control group (74. 4 ± 10. 9),and the difference was statistically significant (t = 3. 732,P = 0. 001). The results of Transwell migration assay showed that the cell number of test group in inferior surface was 136. 5 ± 18. 5,which was significantly higher than that of control group (87. 4 ± 15. 7), and the difference was statistically significant (t = 4. 256,P < 0. 001). Conclusion The expression of miR-210 in breast cancer tissues is high,and its expression is closely related to progression,malignancy and progno-sis of patients. In vitro,miR-210 can promote the malignant behavior of triple negative breast cancer cell line MDA-MB-231. It is a potential molecular marker and targeted treatment site.